MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapy.
Vincent W S LeongSabbir KhanPratibha SharmaShaofang WuRiya R ThomasXiaolong LiSanjay K SinghFrederick F LangAlfred W K YungDimpy KoulPublished in: Neuro-oncology advances (2023)
This research provides a rationale for selectively targeting MGMT-methylated cells using ATRis and TMZ combination. Overall, we believe that MGMT methylation status in GBM could serve as a robust biomarker for patient selection for ATRi combined with TMZ.
Keyphrases
- stem cells
- induced apoptosis
- cell cycle arrest
- case report
- dna methylation
- circulating tumor
- clinical trial
- cell free
- cancer therapy
- genome wide
- cell therapy
- endoplasmic reticulum stress
- gene expression
- oxidative stress
- dna damage response
- drug delivery
- dna damage
- mesenchymal stem cells
- dna repair
- chemotherapy induced